Harbour Capital Advisors LLC cut its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 16.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,513 shares of the company’s stock after selling 1,075 shares during the period. Harbour Capital Advisors LLC’s holdings in Johnson & Johnson were worth $886,000 as of its most recent filing with the SEC.
Other large investors have also made changes to their positions in the company. Innealta Capital LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth approximately $27,000. MFA Wealth Advisors LLC bought a new position in Johnson & Johnson during the second quarter worth $43,000. Fairfield Financial Advisors LTD bought a new stake in Johnson & Johnson in the 2nd quarter valued at $46,000. Fairway Wealth LLC grew its position in Johnson & Johnson by 217.1% in the 2nd quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock worth $49,000 after purchasing an additional 228 shares during the last quarter. Finally, Quarry LP bought a new position in shares of Johnson & Johnson during the 2nd quarter worth about $49,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson Price Performance
Shares of JNJ stock opened at $164.49 on Friday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The stock has a market capitalization of $395.87 billion, a PE ratio of 10.25, a PEG ratio of 2.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock’s fifty day moving average is $162.89 and its 200-day moving average is $154.66.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s payout ratio is 30.92%.
Wall Street Analyst Weigh In
JNJ has been the topic of a number of recent research reports. Royal Bank of Canada lifted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Citigroup lifted their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday. Six research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $175.93.
Read Our Latest Analysis on JNJ
Insider Activity
In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.16% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More
- Five stocks we like better than Johnson & Johnson
- Want to Profit on the Downtrend? Downtrends, Explained.
- Cathie Wood Cuts Robinhood Holdings—Follow Her Lead or Stay Put?
- Upcoming IPO Stock Lockup Period, Explained
- Wave Life Sciences Rockets 70% on Historic RNA Editing Success
- The Significance of Brokerage Rankings in Stock Selection
- UPS vs. FedEx: Which Stock Delivers Better Holiday Gains?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.